Predictive Oncology Inc
For the period ended Dec 31, 2023. Filed Mar 28, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 28, 2024
AGPU$7.64+1.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders’ Equity
CONSOLIDATED STATEMENT OF STOCKHOLDERS’** EQUITY**
FOR THE YEAR ENDED
DECEMBER 31, 2023
| Series B Preferred · Series F Preferred · Common Stock · Additional Paid-In · Accumulated | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Shares · Amount · Shares · Amount · Shares · Amount · Capital · Deficit · Total | ||||||||||
| Balance at 12/31/2022 | 79,246 | $792 | - | $ | - | 3,938,160 | $39,382 | $175,503,634 | $(153,777,916) | $21,765,892 |
| Shares issued to non-employees | - | - | - | - | 98,193 | 982 | 488,344 | - | 489,326 | |
| Vesting expense, net of forfeitures | - | - | - | - | - | - | 2,038 | - | 2,038 | |
| Series F Preferred Stock dividend | - | - | 79,404 | 794 | - | - | (794) | - | - | |
| Reverse stock split round up to whole shares | - | - | - | - | 25,343 | 253 | (253) | - | - | |
| Series F Preferred redemption | - | - | (79,404) | (794) | - | - | 794 | - | - | |
| Share issuance to CFO for vesting of RSUs, net of repurchase to cover withholding tax | - | - | - | - | 1,157 | 12 | (1,521) | - | (1,509) | |
| Net loss | - | - | - | - | - | - | - | (13,983,967) | (13,983,967) | |
| Balance at 12/31/2023 | 79,246 | $792 | - | $ | - | 4,062,853 | $40,629 | $175,992,242 | $(167,761,883) | $8,271,780 |
PREDICTIVE ONCOLOGY INC.
CONSOLIDATED STATEMENT OF STOCKHOLDERS’** EQUITY**
FOR THE YEAR ENDED
DECEMBER 31, 2022
| Series B Preferred · Common Stock · Additional Paid-In · Accumulated | |||||||
|---|---|---|---|---|---|---|---|
| Shares | Amount | Shares | Amount | Capital | Deficit | Total | |
| Balance at 12/31/2021 | 79,246 | $792 | 3,280,750 | $32,808 | $168,272,366 | $(128,040,282) | $40,265,684 |
| Issuance of shares and warrants pursuant to May 2022 private placement, net | - | - | 600,000 | 6,000 | 6,501,050 | - | 6,507,050 |
| Shares issued pursuant to Equity Line | - | - | 15,750 | 158 | 235,851 | - | 236,009 |
| Share issuance to consultant and other | - | - | 29,838 | 297 | 355,827 | - | 356,124 |
| Vesting expense and option repricing | - | - | 11,822 | 119 | 138,540 | - | 138,659 |
| Net loss | - | - | - | - | - | (25,737,634) | (25,737,634) |
| Balance at 12/31/2022 | 79,246 | $792 | 3,938,160 | $39,382 | $175,503,634 | $(153,777,916) | $21,765,892 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.